London, 31 October 2014 – TechNavio has published a new market research report on the Global Prostate Cancer Drugs Market, which is expected to grow at a CAGR of 10.45 percent from 2014-2018.
The market is growing in response to more instances of prostate cancer, due to aging populations in both developed and developing countries.
About the Report
The new report from TechNavio focuses on the major opportunities for pharmaceutical companies in this market. Currently, knowledge about the pathology of prostate cancer is very limited and the curative options available are highly invasive. This lack of knowledge combined with low survival rates has opened plenty of opportunities for companies wanting to break into this market.
“There are currently major discrepancies in the treatment results for early and late stage cancer diagnoses, with patients diagnosed at a later stage having a far worse prognosis. This has provided prospects for pharmaceutical companies to develop new, disease-modifying drugs with improved results for these late-stage diagnoses,” says Faisal Ghaus, Vice President of TechNavio.
“The competition in the market is weak as none of the drugs currently available are efficient enough to address the huge unmet needs prevalent in the market. There is significant space for development of new therapies, which will contribute to steady growth over the projected period.”
Key Information Covered in the Report:
Market segmentation, size and forecast through 2018
Market Growth Drivers:
- Increase in Global Aging Population
- For a full detailed list, view our report.
Market Challenges:
- High Cost of Prostate Cancer Drugs
- For a full detailed list, view our report.
Market Trends:
- Major Opportunities for Pharmaceutical Companies
- For a full detailed list, view our report.
Key Vendors:
- AbbVie Inc.
- AstraZeneca plc
- Janssen Pharmaceuticals Inc.
- Sanofi
Other Prominent Vendors:
- Amgen
- Bayer
- BMS
- Dendreon
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
